Plato Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Plato Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Hold	2,024	–	–	0.01%	422
2026 Q1	$114K	Hold	2,024	–	–	0.01%	428
2025 Q4	$121K	Sell	2,024 -24,793	-92%	-$1.35M	0.01%	413
2025 Q3	$1.44M	Buy	26,817 +10,005	+60%	+$572K	0.1%	212
2025 Q2	$921K	Buy	16,812 +7,410	+79%	+$436K	0.07%	269
2025 Q1	$672K	Hold	9,402	–	–	0.06%	296
2024 Q4	$620K	Buy	9,402 +4,334	+86%	+$290K	0.05%	317
2024 Q3	$356K	Hold	5,068	–	–	0.03%	343
2024 Q2	$417K	Buy	+5,068	New	+$422K	0.04%	289

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Plato Investment Management's BMRN Position: Q2 2026 in Review

Plato Investment Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 2,024 shares worth $115K. The position accounts for 0.01% of the portfolio, ranked #422.

Plato Investment Management first reported a position in BMRN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.44M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Plato Investment Management held 2,024 shares of BioMarin Pharmaceuticals worth $115K as of Q2 2026.
Plato Investment Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.01% of Plato Investment Management's portfolio in Q2 2026, its #422 holding.
Plato Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Plato Investment Management's BioMarin Pharmaceuticals position peaked at $1.44M in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Plato Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.